BOULDER, CO — November 4, 2025 — Leads & Copy —
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) reported a 57% increase in revenues for the quarter and a 38% increase for the six months ended September 30, 2025, compared to the same periods last year. U.S. revenue saw a 115% increase for the quarter and an 86% increase for the six months. The net loss per share decreased by 46% for the quarter and 42% for the six months.
Amy Trombly, CEO of Sonoma Pharmaceuticals, noted the highest quarterly revenues in the company’s history, reaching $5.6 million for the three months ended September 30, 2025. The company has improved its product offerings and expanded its distribution network through new partnerships.
Business highlights include launching HOCl-based diaper rash products into Walmart stores, Reliefacyn® earning the National Psoriasis Foundation (NPF) Seal of Recognition, successful registration of its manufacturing facility, and launching a new HOCl wound cleanser for Medline Industries, LP.
Key financial results for the quarter ended September 30, 2025, include total revenues of $5.6 million, a gross profit of $2.1 million (38% of revenue), and a net loss of $0.5 million. Total revenues for the six months ended September 30, 2025, reached $9.6 million, with a gross profit of $3.6 million (37% of revenue) and a net loss of $1.8 million. As of September 30, 2025, Sonoma had cash and cash equivalents of $3.0 million.
Contact: Sonoma Pharmaceuticals, Inc., ir@sonomapharma.com
Source: Sonoma Pharmaceuticals, Inc.
